DGAP-News
MagForce AG: MagForce AG to present at dbAccess German, Swiss & Austrian Conference 2014, held by Deutsche Bank from June 11-13 in Berlin
DGAP-News: MagForce AG / Key word(s): Miscellaneous
MagForce AG: MagForce AG to present at dbAccess German, Swiss &
Austrian Conference 2014, held by Deutsche Bank from June 11-13 in
Berlin
02.06.2014 / 09:00
---------------------------------------------------------------------
Berlin, Germany and Nevada, USA, June 2, 2014 - MagForce AG (Frankfurt,
Entry Standard, XETRA: MF6), a leading medical device company in the field
of nanomedicine focused on oncology, today announced that it will
participate in the dbAccess German, Swiss & Austrian Conference 2014 held
by Deutsche Bank from June 11 until June 13, 2014, in Berlin, Germany.
Meeting Details:
Speaker: Dr. Ben J. Lipps
Date of presentation: Friday, June 13, 2014; 08:00 am CET
Location: Hotel Adlon Kempinski, Unter den Linden 77, 10117 Berlin
Availability for 1-on-1-meetings: Wednesday, June 11, 2014; 12:30 - 18:30
CET & Friday, June 13, 2014; all day
The presentation will be also made available on Magforce's website on
www.magforce.com.
About MagForce AG
MagForce AG, listed in the entry standard (MF6), together with its
subsidiary MAGFORCE USA, Inc. is a leading medical device company in the
field of nanomedicine in oncology. The Group's proprietary NanoTherm(R)
therapy enables the targeted treatment of solid tumors through the
intratumoral generation of heat via activation of superparamagnetic
nanoparticles. NanoTherm(R), NanoPlan(R), and NanoActivator(R) are
components of the therapy and have received EU-wide regulatory approval as
medical devices for the treatment of brain tumors. MagForce, NanoTherm,
NanoPlan, and NanoActivator are trademarks of MagForce AG in selected
countries. For more information, please visit www.magforce.com.
Disclaimer
This release may contain forward-looking statements and information which
may be identified by formulations using terms such as "expects", "aims",
"anticipates", "intends", "plans", "believes", "seeks", "estimates" or
"will". Such forward-looking statements are based on our current
expectations and certain assumptions, which may be subject to a variety of
risks and uncertainties. The results actually achieved by MagForce AG may
substantially differ from these forward-looking statements. MagForce AG
assumes no obligation to update these forward-looking statements or to
correct them in case of developments, which differ from those, anticipated.
Contact:
Anne Hennecke
MC Services AG
T +49 211 529252-22
F +49 211 529252-29
Email: anne.hennecke@mc-services.eu
End of Corporate News
---------------------------------------------------------------------
02.06.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: MagForce AG
Max-Planck-Straße 3
12489 Berlin
Germany
Phone: +49 (0)30 308 380 0
Fax: +49 (0)30 308 380 99
E-mail: info@magforce.com
Internet: www.magforce.com
ISIN: DE000A0HGQF5
WKN: A0HGQF
Listed: Freiverkehr in Berlin, Düsseldorf, Stuttgart; Frankfurt in
Open Market (Entry Standard)
End of News DGAP News-Service
---------------------------------------------------------------------
271516 02.06.2014
Berlin, Germany and Nevada, USA, June 2, 2014 - MagForce AG (Frankfurt,
Entry Standard, XETRA: MF6), a leading medical device company in the field
of nanomedicine focused on oncology, today announced that it will
participate in the dbAccess German, Swiss & Austrian Conference 2014 held
by Deutsche Bank from June 11 until June 13, 2014, in Berlin, Germany.
Meeting Details:
Speaker: Dr. Ben J. Lipps
Date of presentation: Friday, June 13, 2014; 08:00 am CET
Location: Hotel Adlon Kempinski, Unter den Linden 77, 10117 Berlin
Availability for 1-on-1-meetings: Wednesday, June 11, 2014; 12:30 - 18:30
CET & Friday, June 13, 2014; all day
The presentation will be also made available on Magforce's website on
www.magforce.com.
About MagForce AG
MagForce AG, listed in the entry standard (MF6), together with its
subsidiary MAGFORCE USA, Inc. is a leading medical device company in the
field of nanomedicine in oncology. The Group's proprietary NanoTherm(R)
therapy enables the targeted treatment of solid tumors through the
intratumoral generation of heat via activation of superparamagnetic
nanoparticles. NanoTherm(R), NanoPlan(R), and NanoActivator(R) are
components of the therapy and have received EU-wide regulatory approval as
medical devices for the treatment of brain tumors. MagForce, NanoTherm,
NanoPlan, and NanoActivator are trademarks of MagForce AG in selected
countries. For more information, please visit www.magforce.com.
Disclaimer
This release may contain forward-looking statements and information which
may be identified by formulations using terms such as "expects", "aims",
"anticipates", "intends", "plans", "believes", "seeks", "estimates" or
"will". Such forward-looking statements are based on our current
expectations and certain assumptions, which may be subject to a variety of
risks and uncertainties. The results actually achieved by MagForce AG may
substantially differ from these forward-looking statements. MagForce AG
assumes no obligation to update these forward-looking statements or to
correct them in case of developments, which differ from those, anticipated.
Contact:
Anne Hennecke
MC Services AG
T +49 211 529252-22
F +49 211 529252-29
Email: anne.hennecke@mc-services.eu
End of Corporate News
---------------------------------------------------------------------
02.06.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: MagForce AG
Max-Planck-Straße 3
12489 Berlin
Germany
Phone: +49 (0)30 308 380 0
Fax: +49 (0)30 308 380 99
E-mail: info@magforce.com
Internet: www.magforce.com
ISIN: DE000A0HGQF5
WKN: A0HGQF
Listed: Freiverkehr in Berlin, Düsseldorf, Stuttgart; Frankfurt in
Open Market (Entry Standard)
End of News DGAP News-Service
---------------------------------------------------------------------
271516 02.06.2014
Diskutieren Sie über die enthaltenen Werte
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte